Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Last Updated: Wednesday, September 22, 2021
In the phase II DESTINY-Lung01 trial, Bob T. Li, MD, PhD, MPH, and colleagues found that fam-trastuzumab deruxtecan-nxki produced durable responses in a high proportion of patients with previously treated HER2-mutant non–small cell lung cancer
Advertisement
News & Literature Highlights